The monthly cost will fall to about $675 for patients
WEDNESDAY, Feb. 25, 2026 (HealthDay News) — Some of the most popular diabetes and weight-loss drugs in the U.S. will soon cost a lot less.
Novo Nordisk announced Tuesday that it will cut U.S. list prices of Ozempic and Wegovy by up to 50% starting next year.
The lower prices will take effect Jan. 1, 2027, the same time that reduced prices begin under Medicare plans for older people.
As part of the change, Ozempic and Wegovy will each cost about $675 per month. That’s half the current price of Wegovy and about a 35% drop for Ozempic, which is used to help treat diabetes. Both are injectable drugs.
The company said the price cuts will also apply to Wegovy pills and Rybelsus, another diabetes medication. All doses of these drugs are included.
Novo Nordisk said the move aligns with its goal of making these medicines, commonly known as GLP-1s, more affordable as competition grows.
The market for these drugs has become more crowded in recent years. At the same time, more people are buying them without insurance, making pricing an even bigger concern.
More information
The Cleveland Clinic has more on GLP-1s.
SOURCE: NBC News, Feb. 24, 2026
Calorie Restriction and Mediterranean-Style Diet Yield Similar Weight Loss 
Reinitiating Obesity Meds After Bariatric Surgery Tied to Greater One-Year Weight Loss in Youths 
Weight Cycling Linked to Increased Loss of Muscle Volume 
Compounded GLP-1 Receptor Agonists Remain Widely Available 
Central Adiposity Reclassifies Cardiovascular Risk Across BMI Spectrum 
Feelings of Hunger Gradually Return With Semaglutide Use 
Obesity Treatment for U.S. Adolescents and Young Adults Shifted Rapidly From 2022 to 2026 
Setmelanotide Beneficial in Acquired Hypothalamic Obesity 
